# SCTC21C

Source: https://onco.cc/drugs/sctc21c/  
OnCo record `sctc21c` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SCTC21C is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for multiple myeloma, with its target not yet stated publicly.

## Summary

SCTC21C is an investigational agent whose form is not stated in the registry developed by Sinocelltech. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Pharmaceutical form: Solution for infusion； Route of administration: Subcutaneous. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07297329 (A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant), in multiple myeloma. The largest, NCT07297329, plans to enrol 292 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: not stated (registered as a drug or biological on ClinicalTrials.gov)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of SCTC21C: https://clinicaltrials.gov/search?intr=SCTC21C
- Sponsor page: https://www.sinocelltech.com

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Sinocelltech](https://onco.cc/companies/sinocelltech/)
- trials: [A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant](https://onco.cc/trials/nct07297329/)

---
JSON: https://onco.cc/api/v1/entities/sctc21c.json